Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Wilma J Teubel"'
Autor:
Geert J L H van Leenders, Rajesh Sookhlall, Wilma J Teubel, Corrina M A de Ridder, Suzanne Reneman, Andrea Sacchetti, Kees J Vissers, Wytske van Weerden, Guido Jenster
Publikováno v:
PLoS ONE, Vol 6, Iss 11, p e26753 (2011)
Prostate cancer consists of secretory cells and a population of immature cells. The function of immature cells and their mutual relation with secretory cells are still poorly understood. Immature cells either have a hierarchical relation to secretory
Externí odkaz:
https://doaj.org/article/431f6bd87c96437da1fa61c2a6d7647f
Autor:
Annelies Van Hemelryk, Ingrid Tomljanovic, Corrina M. A. de Ridder, Debra C. Stuurman, Wilma J. Teubel, Sigrun Erkens-Schulze, Esther I. Verhoef, Sebastiaan Remmers, Amrish J. Mahes, Geert J. L. H. van Leenders, Martin E. van Royen, Harmen J. G. van de Werken, Magda Grudniewska, Guido W. Jenster, Wytske M. van Weerden
Publikováno v:
Cells, Vol 11, Iss 22, p 3632 (2022)
Castration-resistant prostate cancer (CRPC) remains an incurable and lethal malignancy. The development of new CRPC treatment strategies is strongly impeded by the scarcity of representative, scalable and transferable preclinical models of advanced,
Externí odkaz:
https://doaj.org/article/9ed70a04355a4fed8481dd542b4ecb2b
Autor:
J. Matthijs Moll, Johannes Hofland, Wilma J. Teubel, Corina M. A. Ridder, Angela E. Taylor, Ralph Graeser, Wiebke Arlt, Guido W. Jenster, Wytske M. Weerden
Publikováno v:
Prostate, 82(5), 505-516. Wiley-Liss Inc.
Introduction: Castration-resistant prostate cancer (CRPC) remains dependent on androgen receptor (AR) signalling, which is largely driven by conversion of adrenal androgen precursors lasting after castration. Abiraterone, an inhibitor of the steroido
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1e68cfabc385d5276f89da108ea9fc9
https://pure.eur.nl/en/publications/dda85665-067a-4a37-ae55-745ebadef787
https://pure.eur.nl/en/publications/dda85665-067a-4a37-ae55-745ebadef787
Autor:
Martin E. van Royen, G. Jenster, Robert J. van Soest, Yukio Homma, Jinpei Kumagai, Ronald de Wit, Wilma J Teubel, Pim J. French, Jan Matthijs Moll, Wytske M. van Weerden
Publikováno v:
Prostate, 79(9), 937-948. Wiley-Liss Inc.
The Prostate
The Prostate
Background: Intratumoral steroidogenesis and its potential relevance in castration‐ resistant prostate cancer (CRPC) and in cytochrome P450, family 17, subfamily A, polypeptide 1 (CYP17A1)‐inhibitor treated hormone‐naive and patients with CRPC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c55b78543e73b5a1cfaba280abe7d50
https://pure.eur.nl/en/publications/fd38955b-d670-454a-b06c-a242adae3b03
https://pure.eur.nl/en/publications/fd38955b-d670-454a-b06c-a242adae3b03
Autor:
Erik A.C. Wiemer, W.M. van Weerden, Ron H.J. Mathijssen, Wilma J Teubel, R.J. van Soest, Jan Matthijs Moll, M.E. van Royen, R. de Wit, E.S. de Morrée
Publikováno v:
European Journal of Cancer, 49(18), 3821-3830. Elsevier Ltd.
INTRODUCTION: Treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years with the introduction of cabazitaxel, abiraterone and enzalutamide. With new systemic therapies available, the opt
Autor:
Guido Jenster, Wytske M. van Weerden, Jan Matthijs Moll, Ralph Graeser, Wilma J Teubel, Ian D. Hickson
Publikováno v:
Journal of Urology. 191
Autor:
Jan Matthijs Moll, Wilma J. Teubel, Sigrun E. Erkens, Ashraf Jozefzoon-Agai, Natasja F. Dits, Angelique van Rijswijk, Guido W. Jenster, Wytske M. van Weerden
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Treatment of prostate cancer (PCa) has changed considerably in the last decade due to the introduction of novel androgen receptor (AR)-targeted agents (ARTAs) for patients progressing on androgen deprivation therapy (ADT). Preclinical research howeve
Externí odkaz:
https://doaj.org/article/045375e7c7834cbe9434ec60597027e4